We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.
- Authors
Lacouture, Mario E; Mitchell, Edith P; Piperdi, Bilal; Pillai, Madhavan V; Shearer, Heather; Iannotti, Nicholas; Xu, Feng; Yassine, Mohamed
- Abstract
Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is approved in the United States and Europe for the treatment of refractory metastatic colorectal cancer (mCRC). Skin toxicities are the most common adverse events with EGFR inhibitors. This is the first study designed to examine differences between pre-emptive and reactive skin treatment for specific skin toxicities in patients with mCRC for any EGFR inhibitor.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 8, p1351
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.21.7828